IRINOTECAN INTAS irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial

Land: Australien

Språk: engelska

Källa: Department of Health (Therapeutic Goods Administration)

Aktiva substanser:

irinotecan hydrochloride trihydrate, Quantity: 300 mg

Tillgänglig från:

Accord Healthcare Pty Ltd

Läkemedelsform:

Injection, concentrated

Sammansättning:

Excipient Ingredients: hydrochloric acid; sodium hydroxide; lactic acid; water for injections; sorbitol

Administreringssätt:

Intravenous Infusion

Enheter i paketet:

1

Receptbelagda typ:

(S4) Prescription Only Medicine

Terapeutiska indikationer:

Irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Produktsammanfattning:

Visual Identification: A pale yellow clear solution; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Bemyndigande status:

Registered

Tillstånd datum:

2020-03-05